Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation.
Buda G, Del Giudice ML, Antonioli E, Ghio F, Orciuolo E, Morganti R, Martini F, Staderini M, Galimberti S, Petrini M. Buda G, et al. Among authors: galimberti s. Front Med (Lausanne). 2021 Aug 27;8:712070. doi: 10.3389/fmed.2021.712070. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34513878 Free PMC article.
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia.
Grassi S, Palumbo S, Mariotti V, Liberati D, Guerrini F, Ciabatti E, Salehzadeh S, Baratè C, Balducci S, Ricci F, Buda G, Iovino L, Mazziotta F, Ghio F, Ercolano G, Di Paolo A, Cecchettini A, Baldini C, Mattii L, Pellegrini S, Petrini M, Galimberti S. Grassi S, et al. Among authors: galimberti s. Front Oncol. 2019 Jun 24;9:532. doi: 10.3389/fonc.2019.00532. eCollection 2019. Front Oncol. 2019. PMID: 31293972 Free PMC article.
Different types of amyloid concomitantly present in the same patients.
Martini F, Buda G, De Tata V, Galimberti S, Orciuolo E, Masini M, Petrini M. Martini F, et al. Among authors: galimberti s. Hematol Rep. 2019 Dec 4;11(4):7996. doi: 10.4081/hr.2019.7996. eCollection 2019 Nov 29. Hematol Rep. 2019. PMID: 31871608 Free PMC article.
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results.
Fazzi R, Petrini I, Giuliani N, Morganti R, Carulli G, Dalla Palma B, Notarfranchi L, Galimberti S, Buda G. Fazzi R, et al. Among authors: galimberti s. Front Immunol. 2021 Feb 3;11:573156. doi: 10.3389/fimmu.2020.573156. eCollection 2020. Front Immunol. 2021. PMID: 33613510 Free PMC article. Clinical Trial.
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study.
Del Giudice ML, Gozzetti A, Antonioli E, Attucci I, Pengue L, Cassano Cassano R, Ghio F, Orciuolo E, Simoncelli M, Bocchia M, Galimberti S, Buda G. Del Giudice ML, et al. Among authors: galimberti s. Eur J Haematol. 2022 Oct;109(4):373-380. doi: 10.1111/ejh.13819. Epub 2022 Jul 13. Eur J Haematol. 2022. PMID: 35749094 Free PMC article.
MDR1 diplotypes as prognostic markers in multiple myeloma.
Maggini V, Buda G, Martino A, Presciuttini S, Galimberti S, Orciuolo E, Barale R, Petrini M, Rossi AM. Maggini V, et al. Among authors: galimberti s. Pharmacogenet Genomics. 2008 May;18(5):383-9. doi: 10.1097/FPC.0b013e3282f82297. Pharmacogenet Genomics. 2008. PMID: 18408561
446 results